These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 35948038)

  • 1. Perioperative Systemic Therapy for Resectable Non-Small Cell Lung Cancer.
    Muthusamy B; Patil PD; Pennell NA
    J Natl Compr Canc Netw; 2022 Aug; 20(8):953-961. PubMed ID: 35948038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer.
    Parekh J; Parikh K; Reuss JE; Friedlaender A; Addeo A
    Curr Oncol Rep; 2023 Aug; 25(8):913-922. PubMed ID: 37249833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.
    Christopoulos P
    Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Decisions for Resectable Non-Small-Cell Lung Cancer: Balancing Less With More?
    O'Reilly D; Botticella A; Barry S; Cotter S; Donington JS; Le Pechoux C; Naidoo J
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e389950. PubMed ID: 37220324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant therapy in non-small cell lung cancer.
    Grant C; Hagopian G; Nagasaka M
    Crit Rev Oncol Hematol; 2023 Oct; 190():104080. PubMed ID: 37532102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Perioperative Immunotherapy for Resectable Non-Small Cell Lung Cancer: Current Evidence and New Standard of Care].
    Le UT; Ohm B; Schmid S
    Zentralbl Chir; 2024 Aug; 149(S 01):S35-S44. PubMed ID: 39137760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Progress in Neoadjuvant Immunotherapies for Resectable Non-small Cell Lung Cancer].
    Wang S; Mao Y
    Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):371-380. PubMed ID: 32283581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer].
    Qi C; Tian P; Li W
    Zhongguo Fei Ai Za Zhi; 2024 Feb; 27(2):138-146. PubMed ID: 38453446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of New Systemic Adjuvant Therapies for Non-small Cell Lung Cancer: Role of the Surgeon.
    Donington JS; Gitlitz B; Lim E; Opitz I; Kim YT; Altorki N
    Ann Thorac Surg; 2023 Jun; 115(6):1544-1555. PubMed ID: 36174774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibition in early-stage non-small cell lung cancer.
    Cuppens K; Du Pont B; Knegjens J; Maes B; Baas P
    Lung Cancer; 2024 Jul; 193():107855. PubMed ID: 38896941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.
    Tieu BH; Sanborn RE; Thomas CR
    Thorac Surg Clin; 2008 Nov; 18(4):403-15. PubMed ID: 19086609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
    Liu X; Xing H; Liu H; Chen J
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
    Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
    Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
    Catania C; Muthusamy B; Spitaleri G; Del Signore E; Pennell NA
    Clin Lung Cancer; 2022 Mar; 23(2):108-115. PubMed ID: 34952792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant immunotherapy in resectable non-small cell lung cancer.
    Lochrin SE; Forde PM
    Clin Adv Hematol Oncol; 2023 Aug; (8):415-423. PubMed ID: 37530615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of surgery in a novel multimodal therapeutic approach to complete cure of advanced lung cancer: current and future perspectives.
    Yamane M; Toyooka S
    Surg Today; 2022 Jan; 52(1):1-11. PubMed ID: 33738585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in patients with early stage resectable nonsmall cell lung cancer.
    Ghysen K; Vansteenkiste J
    Curr Opin Oncol; 2019 Jan; 31(1):13-17. PubMed ID: 30325753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
    Kang J; Zhang C; Zhong WZ
    Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perioperative Immunotherapy in Non-Small Cell Lung Cancer.
    O'Brien J; Bodor JN
    Curr Treat Options Oncol; 2023 Dec; 24(12):1790-1801. PubMed ID: 38091187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
    Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
    Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.